Graphical abstract from Single-Cell Spatial Analysis Identifies Regulators of Brain Tumor–Initiating Cells

Graphical abstract from Single-Cell Spatial Analysis Identifies Regulators of Brain Tumor–Initiating Cells

<p>Graphical abstract. A multi-omics analysis of the glioblastoma tumor microenvironment revealed that biglycan, predominantly expressed by inflammatory BTICs, drives tumor growth. The graphics were generated with Biorender.com.</p>

Shranjeno v:

Bibliografske podrobnosti
Glavni avtor:	Reza Mirzaei (15306062) (author)
Drugi avtorji:	Charlotte D'Mello (15306065) (author), Marina Liu (15306068) (author), Ana Nikolic (15306071) (author), Mehul Kumar (15306074) (author), Frank Visser (15306077) (author), Pinaki Bose (15306080) (author), Marco Gallo (8808401) (author), V. Wee Yong (15306083) (author)
Izdano:	2025
Teme:	Cancer Tumor Biology Molecular and Cellular Biology CNS Cancers Gliomas, Glioblastomas Stem Cell Biology Cancer stem cells Tumor Heterogeneity
Oznake:	Označite Brez oznak, prvi označite!

Podobne knjige/članki

Supplementary Table S1 from Single-Cell Spatial Analysis Identifies Regulators of Brain Tumor–Initiating Cells
od: Reza Mirzaei (15306062)
Izdano: (2025)

Supplementary Table S2 from Single-Cell Spatial Analysis Identifies Regulators of Brain Tumor–Initiating Cells
od: Reza Mirzaei (15306062)
Izdano: (2025)

Figure S1 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
od: Michael Kilian (16697663)
Izdano: (2025)

Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
od: Michael Kilian (16697663)
Izdano: (2025)

Figure S3 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
od: Michael Kilian (16697663)
Izdano: (2025)

Supplementary Figures from Distinct Cell Adhesion Signature Defines Glioblastoma Myeloid-Derived Suppressor Cell Subsets
od: Defne Bayik (14961098)
Izdano: (2025)

Table S1 from A Single-Cell Taxonomy Predicts Inflammatory Niche Remodeling to Drive Tissue Failure and Outcome in Human AML
od: Lanpeng Chen (16918293)
Izdano: (2025)

Table S2 from A Single-Cell Taxonomy Predicts Inflammatory Niche Remodeling to Drive Tissue Failure and Outcome in Human AML
od: Lanpeng Chen (16918293)
Izdano: (2025)

Table S3 from A Single-Cell Taxonomy Predicts Inflammatory Niche Remodeling to Drive Tissue Failure and Outcome in Human AML
od: Lanpeng Chen (16918293)
Izdano: (2025)

Table S4 from A Single-Cell Taxonomy Predicts Inflammatory Niche Remodeling to Drive Tissue Failure and Outcome in Human AML
od: Lanpeng Chen (16918293)
Izdano: (2025)

Table S5 from A Single-Cell Taxonomy Predicts Inflammatory Niche Remodeling to Drive Tissue Failure and Outcome in Human AML
od: Lanpeng Chen (16918293)
Izdano: (2025)

Table S6 from A Single-Cell Taxonomy Predicts Inflammatory Niche Remodeling to Drive Tissue Failure and Outcome in Human AML
od: Lanpeng Chen (16918293)
Izdano: (2025)

Table S7 from A Single-Cell Taxonomy Predicts Inflammatory Niche Remodeling to Drive Tissue Failure and Outcome in Human AML
od: Lanpeng Chen (16918293)
Izdano: (2025)

Supplementary Data from PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING–Type I Interferon Signaling in Glioblastoma
od: Isha Mondal (16721699)
Izdano: (2025)

Supplementary video from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
od: Min Wu (14962986)
Izdano: (2025)

Table S1 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
od: Min Wu (14962986)
Izdano: (2025)

Table S2 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
od: Min Wu (14962986)
Izdano: (2025)

Table S3 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
od: Min Wu (14962986)
Izdano: (2025)

Data Sheet 1_MRI-based radiomic clustering identifies a glioblastoma subtype enriched for neural stemness and proliferative programs.csv
od: Zhongyi Zhang (219440)
Izdano: (2025)

Data Sheet 2_MRI-based radiomic clustering identifies a glioblastoma subtype enriched for neural stemness and proliferative programs.pdf
od: Zhongyi Zhang (219440)
Izdano: (2025)

Supplementary Data 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
od: Francesca Orzan (15055579)
Izdano: (2025)

Supplementary Data 2 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
od: Francesca Orzan (15055579)
Izdano: (2025)

Supplementary Data 3 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
od: Francesca Orzan (15055579)
Izdano: (2025)

Graphical abstract.
od: Ji-Xin Zhao (22056386)
Izdano: (2025)

Supplementary Figure S1 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
od: Sied Kebir (15048732)
Izdano: (2025)

Supplementary Figure S2 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
od: Sied Kebir (15048732)
Izdano: (2025)

Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
od: Sied Kebir (15048732)
Izdano: (2025)

Supplementary Figure S4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
od: Sied Kebir (15048732)
Izdano: (2025)

Supplementary Tables S1-4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
od: Sied Kebir (15048732)
Izdano: (2025)

Table S2 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
od: Joseph Toker (15399882)
Izdano: (2025)

Table S3 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
od: Joseph Toker (15399882)
Izdano: (2025)

Table S4 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
od: Joseph Toker (15399882)
Izdano: (2025)

Table S5 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
od: Joseph Toker (15399882)
Izdano: (2025)

Table S6 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
od: Joseph Toker (15399882)
Izdano: (2025)

Table S7 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
od: Joseph Toker (15399882)
Izdano: (2025)

Table S8 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
od: Joseph Toker (15399882)
Izdano: (2025)

Source Data from Ablation of p57<sup>+</sup> Quiescent Cancer Stem Cells Suppresses Recurrence after Chemotherapy of Intestinal Tumors
od: Takeru Oka (15386810)
Izdano: (2025)

Supplementary Table S1 from Ablation of p57<sup>+</sup> Quiescent Cancer Stem Cells Suppresses Recurrence after Chemotherapy of Intestinal Tumors
od: Takeru Oka (15386810)
Izdano: (2025)

Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
od: Qingsheng Xu (17078830)
Izdano: (2025)

Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
od: Qingsheng Xu (17078830)
Izdano: (2025)

Cannot write session to /tmp/vufind_sessions/sess_3fh43i7ikad2gltj051f986aqp